CD274 and ovarian cancer: This study examined whether avelumab (anti-PD-L1) given alone or in combination with pegylated doxorubicin (PLD) is superior to PLD alone in prolonging overall survival in patients with platinum-resistant/platinum-refractory ovarian cancer.